Skip to main content
logo
Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
1.870
+0.060 (3.31%)
At close: Oct 27, 2026, 4:00 PM EDT
1.850
-0.020 (-1.07%)
After-hours: Oct 27, 2026, 7:30 PM EDT

Grace Therapeutics Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Selling, General & Admin
8.228.677.176.688.286.58
Research & Development
2.152.419.514.599.935.56
Operating Expenses
10.3711.0816.6811.2818.2112.14
Operating Income
-10.37-11.08-16.68-11.28-18.21-12.14
Interest & Investment Income
0.620.690.710.910.250.08
Currency Exchange Gain (Loss)
-0.03-0-0.02-0.02-0.07-0.3
Other Non Operating Income (Expenses)
1.390.93.22-2.730.015.34
EBT Excluding Unusual Items
-8.39-9.49-12.77-13.11-18.02-7.02
Merger & Restructuring Charges
----1.49-33.51-3.2
Asset Writedown
-13.53--0-0.09-0.44-0.25
Pretax Income
-21.92-9.49-12.77-14.69-51.97-10.47
Income Tax Expense
-1.7-1.7-3.2-1.83-9.54-0.65
Net Income
-20.22-7.79-9.57-12.85-42.43-9.82
Net Income to Common
-20.22-7.79-9.57-12.85-42.43-9.82
Net Income Growth
------
Shares Outstanding (Basic)
1717121076
Shares Outstanding (Diluted)
1717121076
Shares Change
26.32%36.59%26.85%28.16%21.09%148.46%
EPS (Basic)
-1.20-0.47-0.79-1.35-5.71-1.60
EPS (Diluted)
-1.20-0.47-0.79-1.35-5.71-1.60
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-10.29-8.87-14.9-12.36-15.93-17.23
Free Cash Flow Per Share
-0.61-0.54-1.23-1.30-2.14-2.81
EBITDA
-10.36-11.07-16.67-11.27-18.08-11.22
D&A For EBITDA
0.010.010.010.010.120.92
EBIT
-10.37-11.08-16.68-11.28-18.21-12.14
SEC Filings: 10-K · 10-Q